page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Paraldehyde (Paral)

Category:

  • Sedatives

Description:

  • DEA Schedule V Anticonvulsant

Indications:

  • Refractory seizures, status epilepticus, sedation, insomnia

  • Alcohol withdrawal, tetanus, eclampsia

Contraindications:

  • Bronchopulmonary disease, hepatic insufficiency

  • Gastroenteritis with ulceration

Precautions:

  • Pregnancy category C

  • Hepatic impairment

  • Mucous membrane irritation

Adverse Reactions (Side Effects):

  • CNS: addiction syndrome resembling alcoholism, coma, confusion dizziness, drowsiness, flushing, hallucinations, headache, seizures, stimulation

  • CV: circulatory collapse, pulmonary edema, pulmonary hemorrhage

  • GI: foul breath, hepatitis, irritation

  • HEME: agranulocytosis, hemolytic anemia, leukopenia, neutropenia, thrombocytopenia

  • RESP: respiratory depression

  • SKIN: erythema, fat necrosis, local pain, rash, sloughing

Dosage:

Administered orally, rectally, intravenously, intramuscularly

  • Adult:            

    • Seizures: 

      • IM 5-10ml; divide 10ml into 2 injections

      • IV 0.2-0.4 ml/kg in NS

    • Alcohol withdrawal: 

      • PO/PR 5-10ml, not to exceed 60ml

      • IM 5ml every 4-6 hours for 24 hours, then every 6 hours on following days, not to exceed 30ml

    • Sedation: 

      • PO/PR 4-10ml

      • IM 5ml; IV 3-5ml (emergency only)

    • Tetanus: 

      • IV 4-5ml or 12ml by gastric tube every 4 hours diluted with water; 

      • IM 5-10ml as needed

  • Child:            

    • Seizures: 

      • IM 0.15 ml/kg; PR 0.3 ml/kg every 4-6 hours or 1 ml/yr of age, not to exceed 5ml; may repeat in 1 hour as needed

      • IV 5ml/90ml NS injection; begin INF at 5 ml/hr; titrate to patient response

    • Sedation: 

      • PO/PR/IM 0.15 ml/kg

Special Considerations:

  •  Injectable form no longer commercially available

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

Advertise on this site